Today: 24 December 2025
Subscribe
Browse Category

NASDAQ:WVE News 27 June 2025 - 18 December 2025

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday
18 December 2025
 ·  ·  ·  ·  · 
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Key takeaways WVE stock today: from under‑the‑radar biotech to market spotlight Wave Life Sciences Ltd. (NASDAQ: WVE),
11 December 2025
 ·  ·  ·  ·  · 
Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

Most Active Stocks Today (December 9, 2025): Nvidia, Tesla, Wave Life Sciences and Confluent Lead a Fed-Focused Wall Street

New York — December 9, 2025 US investors are crowding into a tight cluster of high-conviction themes today: artificial intelligence chips, blockbuster media and software deals, obesity drugs, and speculative AI small caps. Coming into Tuesday’s session (December 9), Wall
9 December 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about
9 December 2025
 ·  ·  ·  ·  ·  · 
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and
8 December 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Key facts (quick read) In‑depth report 1) Huntington’s disease, in plain English What it is. HD is a progressive brain disorder that typically begins in mid‑adulthood, causing a mix of movement (chorea, dystonia), cognitive (processing speed, executive function) and psychiatric symptoms
26 September 2025
 ·  ·  ·  ·  ·  ·  · 
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began
27 June 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop